Scaffold protein of extracellular vesicle and use thereof
By using nerve growth factor receptors as scaffold proteins and combining active domains, the enrichment and distribution in exosomes are improved, the problem of uneven distribution of existing scaffold proteins is solved, and the drug delivery efficiency of exosomes is enhanced and clinical application value.
Patent Information
- Application Number
- PCT/CN2023/105233
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-06
- Filing Date
- 2023-06-30
- Publication Date
- 2024-11-14
AI Technical Summary
The existing extracellular vesicle scaffold proteins are unevenly distributed in exosomes, which affects the efficiency of exosome delivery and limits its clinical application value in the field of drug delivery.
Use nerve growth factor receptors or fragments thereof as scaffold proteins for extracellular vesicles, and bind active domains such as antisense oligonucleotides, siRNA, miRNA, etc. by localizing them to the membrane, inside or outside the membrane of extracellular vesicles. , fusion proteins are formed to improve enrichment and distribution in exosomes.
The high enrichment and uniform distribution of scaffold proteins in exosomes are achieved, the exosome drug carrying capacity and delivery efficiency are improved, and the potential clinical application value in the treatment is enhanced.
Smart Images

Figure PCTCN2023105233-FTAPPB-I100001 
Figure PCTCN2023105233-FTAPPB-I100002 
Figure PCTCN2023105233-FTAPPB-I100003
Abstract
Description
Extracellular vesicle scaffold proteins and their applications Technical Field
[0001] The present invention belongs to the field of biotechnology, and in particular relates to a scaffold protein for extracellular vesicles and an application thereof. Background Art
[0002] Adeno-associated virus (AAV) is considered to be the safest and most promising drug delivery vector due to its extremely low immunogenicity. However, its small loading capacity (less than 4.7k) limits its application in some gene therapy fields. Exosomes are nano-scale particles with low immunogenicity, making them suitable as a drug carrier. Moreover, the volume of exosomes is significantly larger than that of AAV. It has been reported in the literature that exosomes can accommodate 6k of nucleic acid, which has certain advantages over AAV. In natural exosomes, certain proteins are significantly enriched. These proteins can serve as scaffold proteins, and when a certain special protein is fused with the scaffold protein and expressed, this special protein will also be enriched, thereby realizing the loading of proteins and nucleic acids on exosomes. By delivering exosomes to recipient cells, the loaded proteins or nucleic acids can be exerted to achieve a therapeutic effect.
[0003] Some scaffold proteins commonly used in existing technologies, such as CD63 and CD81, are unevenly distributed within exosomes, with only a subset of exosomes containing these proteins. These defects can affect the efficiency of exosome delivery in drug delivery, limiting the potential clinical applications of engineered exosomes. Therefore, the search for novel scaffold proteins is needed to improve the current state of exosome scaffolding.
[0004] Summary of the Invention
[0005] In order to solve the above-mentioned problems existing in the prior art, the present invention provides a scaffold protein for extracellular vesicles. After overexpression, the scaffold protein will not affect cell growth, and the enrichment degree in extracellular vesicles is higher than that of existing scaffold proteins used for treatment. At the same time, the distribution of the screened scaffold protein in extracellular vesicles is at least equivalent to that of commonly used scaffold proteins (such as CD63).
[0006] One aspect of the present invention provides the use of nerve growth factor receptor or a fragment thereof as an extracellular vesicle scaffold protein.
[0007] In some embodiments, the nerve growth factor receptor or fragment thereof is localized in an extracellular vesicle. In some embodiments, the nerve growth factor receptor or fragment thereof is localized on, within, or outside the membrane of an extracellular vesicle. In some embodiments, the nerve growth factor receptor or fragment thereof is localized in the lumen of an extracellular vesicle.
[0008] In some embodiments, the nerve growth factor receptor has at least the amino acid sequence shown in SEQ ID NO:6 or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with SEQ ID NO:6.
[0009] In some embodiments, the nerve growth factor receptor has the amino acid sequence shown in SEQ ID NO:1 or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO:1.
[0010] In some embodiments, the extracellular vesicles include one or more of exosomes, microvesicles, apoptotic bodies, tumor vesicles, and nanovesicles.
[0011] In some embodiments, the extracellular vesicle is a hepatocyte-localized extracellular vesicle.
[0012] Another aspect of the present invention provides an extracellular vesicle, which includes a scaffold protein, wherein the scaffold protein is a nerve growth factor receptor or a fragment thereof; and an active domain that binds to the scaffold protein.
[0013] In some embodiments, the nerve growth factor receptor has at least the amino acid sequence shown in SEQ ID NO:6 or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with SEQ ID NO:6.
[0014] In some embodiments, the nerve growth factor receptor has the amino acid sequence shown in SEQ ID NO:1 or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO:1.
[0015] In some embodiments, the active domain comprises a polypeptide, a polynucleotide sequence, a compound, or any combination thereof.
[0016] In some embodiments, the active domain comprises an antisense oligonucleotide (ASO), siRNA, miRNA, shRNA, a nucleic acid, or any combination thereof.
[0017] In some embodiments, the active domain comprises a peptide, a protein, an antibody, or an antigen-binding fragment thereof, or any combination thereof. Preferably, the antigen-binding fragment of the antibody comprises scFv, (scFv)2, Fab, Fab', F(ab')2, F(ab1)2, Fv, dAb and Fd fragments, bifunctional antibodies, antibody-related polypeptides, or any fragments thereof.
[0018] In some embodiments, the scaffold protein can be bound to the active domain directly or through a linker.
[0019] In some embodiments, the linker is a polypeptide linker and / or a non-polypeptide linker. In some embodiments, the linker can be a (chemical) covalent linker.
[0020] In some embodiments, the active domain comprises a nucleotide binding protein or a fragment thereof, wherein the scaffold protein forms a fusion protein with the nucleotide binding protein or a fragment thereof.
[0021] In some embodiments, the nucleotide binding protein or fragment thereof further binds to the polynucleotide sequence.
[0022] Preferably, the nucleotide binding protein is selected from Ku protein, Sm7 protein, MS2 coat protein, PP7 coat protein, Com RNA binding protein, aptamer ligand, or any combination, functional variant, fragment or domain thereof.
[0023] In some embodiments, the active domain can be displayed on the outer surface of the exosome or in the lumen of the exosome via the scaffold protein nerve growth factor receptor or a fragment thereof disclosed herein.
[0024] Another aspect of the present invention provides an expression system, comprising: a first expression element encoding a scaffold protein, wherein the scaffold protein is a nerve growth factor receptor or a fragment thereof; and a second expression element encoding an active domain.
[0025] In some embodiments, the nerve growth factor receptor has at least the amino acid sequence shown in SEQ ID NO:6 or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with SEQ ID NO:6.
[0026] In some embodiments, the nerve growth factor receptor has the amino acid sequence shown in SEQ ID NO:1 or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO:1.
[0027] In some embodiments, the active domain comprises a polypeptide, a polynucleotide sequence, a compound, or any combination thereof.
[0028] In some embodiments, the active domain comprises an antisense oligonucleotide (ASO), siRNA, miRNA, shRNA, a nucleic acid, or any combination thereof.
[0029] In some embodiments, the active domain comprises a peptide, a protein, an antibody, or an antigen-binding fragment thereof, or any combination thereof. Preferably, the antigen-binding fragment of the antibody comprises scFv, (scFv)2, Fab, Fab', F(ab')2, F(ab1)2, Fv, dAb and Fd fragments, bifunctional antibodies, antibody-related polypeptides, or any fragments thereof.
[0030] In some embodiments, the scaffold protein can be bound to the active domain directly or through a linker.
[0031] In some embodiments, the linker is a polypeptide linker and / or a non-polypeptide linker. In some embodiments, the linker can be a (chemical) covalent linker.
[0032] In some embodiments, the active domain comprises a nucleotide binding protein or a fragment thereof, wherein the scaffold protein forms a fusion protein with the nucleotide binding protein or the fragment thereof.
[0033] In some embodiments, the nucleotide binding protein or fragment thereof further binds to the polynucleotide sequence.
[0034] Preferably, the nucleotide binding protein is selected from Ku protein, Sm7 protein, MS2 coat protein, PP7 coat protein, Com RNA binding protein, aptamer ligand, or any combination, functional variant, fragment or domain thereof.
[0035] In some embodiments, the expression system can be selected from a prokaryotic expression system, a eukaryotic expression system or a viral expression system. In some embodiments, the expression system can include a prokaryotic vector, a eukaryotic vector or a viral vector, etc.
[0036] Another aspect of the present invention provides a host cell comprising the above expression system.
[0037] In some embodiments, the host cell is a prokaryotic cell or a eukaryotic cell. In some embodiments, the prokaryotic cell can be selected from Escherichia coli or Bacillus subtilis, such as Escherichia coli BL21, T7E, C41, Arctic, etc. In some embodiments, the eukaryotic cell can be selected from yeast cells, insect cells, plant cells, mammalian cells, etc., such as yeast cells, CHO cells, 293 cells, Vero cells, NSO cells, etc.
[0038] Another aspect of the present invention provides a pharmaceutical composition comprising the extracellular vesicles described in the second aspect and a pharmaceutically acceptable carrier.
[0039] In some embodiments, the pharmaceutical composition is in the form of a tablet, powder, granule, pill, injection, suspension, powder, emulsion, aerosol, gel, eye drops, sustained release agent or sustained release implant. In some embodiments, the pharmaceutical composition can be formulated into an injectable formulation. In some embodiments, the formulation is suitable for intravitreal injection, subcutaneous, intradermal, intramuscular, intravenous, intrathecal or intraspinal administration.
[0040] Another aspect of the present invention provides use of the extracellular vesicles of the present invention in preparing a medicament for preventing or treating a disease.
[0041] In some embodiments, the disease comprises cancer, an inflammatory disorder, a neurodegenerative disorder, a central nervous system disease, or a metabolic disease.
[0042] In some embodiments, the extracellular vesicles are administered intravenously, intraperitoneally, nasally, orally, intramuscularly, subcutaneously, parenterally, or intratumorally.
[0043] In some embodiments, the extracellular vesicles can be used for drug loading and / or marker loading.
[0044] The present invention provides a new scaffold protein, which provides a new connection basis with higher abundance for drug loading or labeling of extracellular vesicles. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 shows the TEM results of exosomes overexpressing different scaffold proteins.
[0046] FIG2 shows the markers (Western Blot) results of exosomes overexpressing different scaffold proteins.
[0047] Figure 3 shows the HPLC purity characterization results after purification of different exosomes, where a is 293Evs, b is NGFR-Evs, and c is CD63-293Evs.
[0048] Figure 4 shows the HPLC purity characterization results after purification of different exosomes, where a is MFGE8-Evs, b is PTGFRN-Evs, and c is Basp-1-293Evs.
[0049] Figure 5 shows the characterization results of the scaffold distribution ratios of different exosomes.
[0050] Figure 6 shows the results of characterization of the scaffold abundance of different exosomes.
[0051] Figure 7 shows the characterization results of the purity (a), morphology (b), particle size (c) and EGFP protein loading (d) of exosomes overexpressing truncated-NGFR scaffold protein.
[0052] Figure 8 shows the characterization results of the purity (a), particle size (b) and morphology (c) of exosomes NGFR-MCP-MS2-FIX-Fc293Evs after loading mRNA using the RNA-binding protein MCP.
[0053] Figure 9 shows the purity (a), particle size (b), and morphology (c) characterization results of exosome NGFR-L7Ae-C / D box-FIX-Fc293Evs after loading mRNA using the RNA-binding protein L7Ae.
[0054] Figure 10 shows the purity (a), particle size (b) and morphology (c) characterization results of exosome NGFR-FIX-Fc 293Evs without using RNA-binding protein to load mRNA.
[0055] FIG11 shows the purity (a), particle size (b) and morphology (c) characterization results of exosome NGFR 293Evs that were not loaded with mRNA but only overexpressed the NGFR scaffold.
[0056] FIG12 shows the mRNA loading characterization results of NGFR fused with different RNA binding proteins.
[0057] Figure 13 shows the characterization results of the purity (a), particle size (b), morphology (c) and antibody positive rate (d) of NGFR targeting antibody-displaying exosomes CD19scfv-NGFR-EGFP 293Evs.
[0058] FIG14 shows the characterization results of the purity (a), particle size (b), morphology (c), and antibody positive rate (d) of NGFR exosomes NGFR 293Evs that do not display targeting antibodies.
[0059] Figure 15 shows the characterization results of the purity (a), particle size (b), morphology (c) and antibody positivity (d) of exosomes 293Evs from expi 293F cells that do not overexpress NGFR scaffolds.
[0060] FIG16 shows the ELISA column results of the binding of CD19scfv on the surface of exosomes to CD19 antigen.
[0061] Figure 17 shows the characterization results of the exosome purity (a), particle size (b), targeting peptide positive ratio (c) and morphology (d) of NGFR targeting peptide-displaying exosomes gp17-NGFR-EGFP-Flag 293Evs.
[0062] FIG18 shows the characterization results of the exosome purity (a), particle size (b), targeting peptide positive ratio (c) and morphology (d) of NGFR-EGFP-Flag 293Evs exosomes that do not display the targeting peptide.
[0063] Figure 19 shows the characterization results of exosome purity (a), particle size (b), targeting peptide positive ratio (c) and morphology (d) of exosomes 293Evs from expi 293F cells that do not overexpress NGFR scaffold.
[0064] Figure 20 shows the results of NGFR targeting peptide exosome targeting functional organoid detection.
[0065] FIG21 shows the phagocytic distribution results of NGFR-targeting peptide exosomes in liver organoids.
[0066] FIG22 shows the effect of exosomes containing NGFR targeting peptides on the distribution of exosomes in mice. DETAILED DESCRIPTION
[0067] Exosomes are extracellular vesicles secreted by cells with a diameter of 30 to 200 nm. They are rich in RNA (miRNA, lncRNA, circRNA, etc.), DNA, proteins and lipids, and are involved in the transfer of molecules between cells. Exosomes are a highly heterogeneous group, including size heterogeneity, content heterogeneity, functional heterogeneity, and source heterogeneity. Therefore, the types and quantities of molecules rich in exosomes produced by different cells are different, and the types and quantities of molecules rich in exosomes isolated by different exosome purification methods are also different. Exosomes are rich in various molecules. When taken up by cells, they will have different degrees of impact on the recipient cells. Natural exosomes derived from different cells will have some functions of the source cells. By modifying the cells, the function of the exosomes will be affected and used for treatment or drug delivery.
[0068] The nerve growth factor receptor (NGFR) belongs to the tumor necrosis factor transmembrane receptor superfamily and is a low-affinity transmembrane receptor of the neurotrophin family. NGFR is known to bind to nerve growth factor (NGF) and other neurotrophic factors, stimulating nerve growth and regulating the differentiation of sympathetic neurons and some sensory neurons. The present disclosure unexpectedly discovered that NGFR can be enriched in exosomes and can serve as an exosome scaffold protein to transport exogenous proteins or nucleic acids to achieve the desired effect.
[0069] To make the objectives, technical solutions, and advantages of the present invention more clearly understood, the present invention will be further described in detail below with reference to the following examples. The specific embodiments described herein are intended only to illustrate the present invention and are not intended to limit the present invention in any way. In addition, in the following description, descriptions of known structures and technologies are omitted to avoid unnecessary confusion about the concepts of the present disclosure. Such structures and technologies are also described in many publications.
[0070] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly used in the field to which the present invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.
[0071] Unless the context clearly dictates otherwise, as used herein, the expressions "a" and "an" include plural references. For example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth.
[0072] As used herein, the term "about" refers to a range of ±20% of the value that follows. In some embodiments, the term "about" refers to a range of ±10% of the value that follows. In some embodiments, the term "about" refers to a range of ±5% of the value that follows.
[0073] The terms "extracellular vesicle", "exovesicle" or "EV" as used herein refer to cell-derived vesicles comprising a membrane that encapsulates an internal space. Extracellular vesicles include all membrane-bound vesicles (e.g., exosomes, microvesicles, apoptotic bodies, tumor vesicles, nanovesicles, etc.) whose diameters are smaller than the diameter of the cells from which they are derived. In some aspects, the diameter of the extracellular vesicle is in the range of 20 nm to 1000 nm and may be contained within the internal space (i.e., cavity), displayed on the outer surface of the extracellular vesicle and / or across the membrane. In some aspects, the payload may include nucleic acids, proteins, carbohydrates, lipids, small molecules and / or combinations thereof. In some aspects, the extracellular medium comprises a scaffold portion. By way of example and not limitation, extracellular vesicles include apoptotic bodies, cell fragments, cell-derived vesicles obtained by direct or indirect manipulation (e.g., by continuous extrusion or treatment with an alkaline solution), vesicles of vesicled organelles and vesicles produced by living cells (e.g., by direct plasma membrane budding or late endosome fusion with the plasma membrane). The extracellular vesicles can be derived from living or dead organisms, explanted tissues or organs, prokaryotic or eukaryotic cells and / or cultured cells. In some aspects, the extracellular vesicles are produced by cells expressing one or more transgene products.
[0074] As used herein, the term "exosome" refers to an extracellular vesicle with a diameter between 20 and 300 nm (e.g., between 40 and 200 nm). Exosomes comprise a membrane enclosing an interior space and, in some aspects, can be produced by cells by direct plasma membrane budding or by fusion of late endosomes or multivesicular bodies with the plasma membrane. In certain aspects, exosomes comprise a scaffold portion. As described below, exosomes can be derived from producer cells and isolated from producer cells based on their size, density, biochemical parameters, or a combination thereof. In some aspects, the EVs (e.g., exosomes) of the present disclosure are produced by cells expressing one or more transgene products.
[0075] The term "nanovesicle" as used herein refers to an extracellular vesicle with a diameter between 20-250 nm (e.g., between 30-150 nm) and is produced by a cell (e.g., a production cell) by direct or indirect manipulation so that the cell will not produce nanovesicles in the absence of manipulation. Suitable manipulations of cells for the production of nanovesicles include, but are not limited to, continuous extrusion, treatment with an alkaline solution, ultrasonic treatment, or a combination thereof. In some aspects, the nanovesicle colonies described herein are substantially free of vesicles derived from cells by direct budding from the plasma membrane or fusion of late endosomes with the plasma membrane. In some aspects, the nanovesicle comprises a scaffold portion, such as scaffold X and / or scaffold Y. Once derived from production cells, the nanovesicles can be separated from the production cells based on their size, density, biochemical parameters, or a combination thereof.
[0076] The term "fusion protein" as used herein refers to a protein in which two or more proteins or fragments thereof are colinearly linked through their respective peptide backbones using genetic expression of protein-encoding polynucleotides or protein synthesis methods.
[0077] As used herein, the term "antibody" encompasses immunoglobulins (whether produced naturally or partially or completely synthetically) and fragments thereof. The term also covers any protein having a binding domain that is homologous to an immunoglobulin binding domain. "Antibody" also includes polypeptides comprising a framework region from an immunoglobulin gene or fragment thereof that specifically binds and recognizes an antigen. The use of the term antibody is intended to include whole antibodies, polyclonal antibodies, monoclonal antibodies and recombinant antibodies, fragments thereof, and also includes single chain antibodies, humanized antibodies, murine antibodies, chimeric monoclonal antibodies, mouse-human monoclonal antibodies, mouse-primate monoclonal antibodies, primate-human monoclonal antibodies, anti-idiotypic antibodies, antibody fragments (such as, for example, scFv, (scFv)2, Fab, Fab' and F(ab')2, F(ab1)2, Fv, dAb and Fd fragments), bifunctional antibodies and antibody-related polypeptides. Antibodies include bispecific antibodies and multispecific antibodies so long as they exhibit the desired biological activity or function.
[0078] As used herein, the terms "active domain" or "biologically active domain" are used interchangeably and refer to any molecule that can be linked to a scaffold protein via an anchoring moiety, wherein the molecule can have a therapeutic or prophylactic effect in a subject in need thereof, or can be used for diagnostic purposes. Thus, for example, the term biologically active domain includes proteins (e.g., antibodies, proteins, polypeptides, and derivatives, fragments, and variants thereof), polynucleotide sequences, or chemical compounds, and in some embodiments, the biologically active domain includes antisense oligonucleotides (ASOs), siRNAs, miRNAs, shRNAs, or nucleic acids. In some embodiments, the antigen-binding fragment of an antibody includes scFv, (scFv)2, Fab, Fab', F(ab')2, F(ab1)2, Fv, dAb, and Fd fragments, bifunctional antibodies, or antibody-related polypeptides.
[0079] As used herein, the term "polynucleotide" refers to a polymer of nucleotides of any length, including ribonucleotides, deoxyribonucleotides, analogs thereof, or mixtures thereof. This term refers to the primary structure of the molecule. Thus, the term includes triple-stranded, double-stranded, and single-stranded deoxyribonucleic acids ("DNA"), as well as triple-stranded, double-stranded, and single-stranded ribonucleic acids ("RNA"). It also includes modified (e.g., by alkylation and / or by capping) and unmodified forms of polynucleotides. More specifically, the term "polynucleotide" includes polydeoxyribonucleotides (containing 2-deoxy-D-ribose); polyribonucleotides (containing D-ribose), including tRNA, rRNA, hRNA, siRNA, and mRNA, whether spliced or unspliced; any other type of polynucleotide that is an N- or C-glycoside of a purine or pyrimidine base; and other polymers containing an orthonucleotide backbone, such as polyamides (e.g., peptide nucleic acid "PNA") and polymorpholino polymers; and other synthetic, sequence-specific nucleic acid polymers, provided that the polymer contains nucleobases in a configuration that permits base pairing and base stacking, such as found in DNA and RNA.
[0080] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to amino acid polymers of any length. The polymers may comprise modified amino acids. The terms also encompass amino acid polymers that have been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more amino acid analogs (including, for example, unnatural amino acids such as homocysteine, ornithine, p-acetylphenylalanine, D-amino acids, and creatine), as well as other modifications known in the art.
[0081] As used herein, the term "polypeptide" refers to proteins, polypeptides, and peptides of any size, structure, or function. Polypeptides include gene products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, transverse homologs, fragments of the aforementioned, and other equivalents, variants, and analogs. Polypeptides can be single polypeptides or can be multimolecular complexes, such as dimers, trimers, or tetramers. They can also comprise single-chain or multi-chain polypeptides. Most commonly, disulfide bonds are present in multi-chain polypeptides. The term polypeptide can also be applied to amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding naturally occurring amino acids. In some aspects, a "peptide" can be less than or equal to 50 amino acids long, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.
[0082] As used herein, the term "connector" refers to a peptide or polypeptide sequence (e.g., a synthetic peptide or polypeptide sequence) or a non-polypeptide, such as an alkyl chain. In some embodiments, two or more connecters can be connected in series. When multiple connecters are present, each connecter can be the same or different. In general, the connecter provides flexibility or prevents / improves steric hindrance. The connecter is not typically cut; however, in some aspects, such cutting may be desirable. Therefore, in some embodiments, the connecter may include one or more protease cleavable sites, which may be located within the connecter sequence or flanking the connecter at either end of the connecter sequence.
[0083] In some embodiments, the linker is a peptide linker. In some embodiments, the peptide linker can include at least about two, at least about three, at least about four, at least about five, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95 or at least about 100 amino acids. In some embodiments, the linker includes one or more amino acids. In some embodiments, the linker includes a Gly-Ser (GS) linker. In some embodiments, the GS linker includes (GS)n, where n is an integer between 1 and 10. In some embodiments, the GS linker includes (GS)n, where n is an integer between 1 and 10.
[0084] In some embodiments, the peptide linker is synthetic, i.e., non-naturally occurring. In one aspect, the peptide linker comprises a peptide (or polypeptide) (e.g., a naturally occurring or non-naturally occurring peptide) comprising an amino acid sequence that connects or genetically fuses a first linear amino acid sequence to a second linear amino acid sequence, wherein the first linear amino acid sequence is not naturally connected or genetically fused to the second linear amino acid sequence in nature. For example, in one aspect, the peptide linker may comprise a non-naturally occurring polypeptide that is a modified form of a naturally occurring polypeptide (e.g., comprising a mutation such as an addition, substitution, or deletion).
[0085] The linker may be readily cleaved (a "cleavable linker"), thereby facilitating the release of the exogenous biologically active moiety. In some embodiments, the linker is a "reduction-sensitive linker." In some embodiments, the reduction-sensitive linker comprises a disulfide bond. In some embodiments, the linker is an "acid-labile linker." In some embodiments, the acid-labile linker comprises a hydrazone. Suitable acid-labile linkers also include, for example, cis-aconitic acid linkers, hydrazide linkers, thiocarbamoyl linkers, or any combination thereof. In some embodiments, the ASO is associated with an EV (e.g., an exosome) via a linker. In some embodiments, the linker comprises an acrylic acid phosphoramidite (e.g., ACRYDITE™), adenylation, an azide (NHS Ester), digoxigenin (NHS Ester), cholesterol-TEG, I-LINKER™, an amino modifier (e.g., amino modifier C6, amino modifier C12, amino modifier C6dT, or Uni-Link™ amino modifier), an alkyne, a 5' hexynyl, a 5-octadiynyl dU, biotinylation (e.g., biotin, biotin (azide), biotin dT, biotin-TEG, dual biotin, PC biotin, or desthiobiotin), a thiol modification (thiol modifier C3S-S, dithiol, or thiol modifier C6S-S), or any combination thereof.
[0086] In some embodiments, the linker comprises a terpene such as nerolidol, farnesol, limonene, linalool, geraniol, carvone, fenchone, or menthol; a lipid such as palmitic acid or myristic acid; cholesterol; oleyl; retinyl; a cholesterol residue; cholic acid; adamantaneacetic acid; 1-pyrenebutyric acid; dihydrotestosterone; 1,3-bis-O(hexadecyl)glycerol; geranyloxyhexyl; hexadecylglycerol; borneol; 1,3-propanediol; heptadecyl; O3-(oleoyl)lithocholic acid; O3-(oleoyl)cholic acid; dimethoxytrityl; phenoxazine, a maleimide moiety, glucuronidase type, CL2A-SN38 type, folic acid; a carbohydrate; vitamin A; vitamin E; vitamin K, or any combination thereof. In certain aspects, the ASO comprises a cholesterol tag, and the cholesterol tag is associated with the membrane of an EV (e.g., an exosome). In some embodiments, the linker comprises a non-cleavable linker. In some embodiments, the linker includes tetraethylene glycol (TEG), hexaethylene glycol (HEG), polyethylene glycol (PEG), succinimide or any combination thereof. In some embodiments, the linker includes a spacer unit that connects the bioactive molecule to the linker. In some embodiments, one or more linkers include smaller units (e.g., HEG, TEG, glycerol, C2 to C12 alkyl, etc.) connected together. In one aspect, the linkage is an ester linkage (e.g., phosphodiester or thiophosphate) or other linkage. In some embodiments, the linker includes polyethylene glycol (PEG), characterized in that the formula R3-(O-CH2-CH2)n- or R3-(0-CH2-CH2)nO-, wherein R3 is hydrogen, methyl or ethyl, and the value of n is 2 to 200. In some embodiments, the linker includes a spacer, wherein the spacer is PEG. In some embodiments, the PEG linker is an oligoethylene glycol, such as a diethylene glycol, triethylene glycol, tetraethylene glycol (TEG), pentaethylene glycol, or hexaethylene glycol (HEG) linker.
[0087] As used herein, the term "prevent," "prevent," "prevent," or "prevent" refers to partially or completely delaying the onset of a disease, condition, and / or disorder; partially or completely delaying the onset of one or more symptoms, characteristics, or clinical manifestations of a particular disease, condition, and / or disorder; partially or completely delaying the onset of one or more symptoms, characteristics, or manifestations of a particular disease, condition, and / or disorder; partially or completely delaying the progression from a particular disease, condition, and / or disorder; and / or reducing the risk of developing pathology associated with a disease, condition, and / or disorder.
[0088] As used herein, the term "treat" refers to, for example, reducing the severity of a disease or condition; shortening the duration of the disease; ameliorating or eliminating one or more symptoms associated with the disease or condition; providing a beneficial effect to a subject suffering from the disease or condition, but not necessarily curing the disease or condition. The term also includes preventing or prophylactic treatment of a disease or condition or its symptoms.
[0089] As used herein, the term "replacement" or "substitution" of an amino acid may refer to a conservative amino acid substitution, wherein an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues with similar side chains have been defined in the art and include basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, if an amino acid in a polypeptide is replaced with another amino acid from the same side chain family, the substitution is considered conservative. In another aspect, a string of amino acids can be conservatively substituted with a structurally similar string that differs in the order and / or composition of side chain family members.
[0090] "Percent sequence identity" or "percent identity" between two polynucleotide or polypeptide sequences refers to the number of identical matched positions shared by the sequences over the comparison window, taking into account additions or deletions (i.e., gaps) that must be introduced for optimal alignment of the two sequences. A matched position is any position where the same nucleotide or amino acid is present in both the target sequence and the reference sequence. Since a gap is not a nucleotide or amino acid, gaps present in the target sequence are not counted. Similarly, since target sequence nucleotides or amino acids are counted and nucleotides or amino acids from the reference sequence are not counted, gaps present in the reference sequence are not counted.
[0091] Percentage sequence identity can be calculated by the following process: determine that the number of positions where identical amino acid residues or nucleic acid bases occur in both sequences, to obtain the number of matched positions, the number of matched positions divided by the total number of positions in the comparison window, and multiply the result by 100, to obtain percent sequence identity. The determination of percent sequence identity between the comparison of a sequence and two sequences can be accomplished using software that is easy to use online and download. Suitable software programs can be obtained from various sources for the comparison of protein and nucleotide sequences. A suitable program for determining percent sequence identity is bl2seq, which is a part for the BLAST suite of programs that can be obtained from the BLAST website (blast.ncbi.nlm.nih.gov) of the National Center for Biotechnology Information of the U.S. Government. Bl2seq uses BLASTN or BLASTP algorithms to compare between two sequences. BLASTN is used for comparing nucleic acid sequences, and BLASTP is used for comparing amino acid sequences. Other suitable programs are, for example, Needle, Stretcher, Water or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at www.ebi.ac.uk / Tools / psa.
[0092] The term "pharmaceutically acceptable carrier" as used herein refers to a component of a pharmaceutical formulation other than the active ingredient that is non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.
[0093] The scaffold protein provided by the present invention can be used as a scaffold protein on exosomes and can be used to connect drugs or markers, thereby realizing drug loading function or tracing research. In certain embodiments of the present invention, the scaffold protein can also be modified, such as truncation, mutation, insertion of exogenous sequences or modification. In some embodiments, the N-terminus of the scaffold protein is fused with a short peptide chain, and the short peptide chain can express a targeting peptide, a recombinant peptide, a therapeutic peptide or a linker. In other embodiments, the C-terminus of the scaffold protein is fused with a short peptide chain, and the short peptide chain can express a therapeutic peptide, a recombinant peptide or a linker. In some embodiments, the C-terminus of the scaffold protein is fused with an RNA binding protein, and the RNA binding protein can bind to an RNA containing a special structural domain, and the RNA containing a special structural domain contains a functional region with a medicinal effect and a connecting region for connecting to the RNA binding protein; the RNA used for treatment can be mRNA, miRNA, LncRNA, circRNA or siRNA
[0094] The following examples and accompanying drawings are provided to facilitate understanding of the present invention. However, it should be understood that these examples and accompanying drawings are intended to illustrate the present invention only and are not intended to limit the present invention in any way. The actual scope of protection of the present invention is set forth in the claims. It should be understood that any modifications and variations may be made without departing from the spirit of the present invention.
[0095] Example 1. Expression vector construction
[0096] The NGFR protein (SEQ ID NO: 1) and the control scaffold proteins BASP-1 (SEQ ID NO: 2), PTGFRN (SEQ ID NO: 3), CD63 (SEQ ID NO: 4), and MFGE8 (SEQ ID NO: 5) were used to construct expression plasmids pcDNA3.1 (+) -scaffold protein-EGFP-Nanoluc.
[0097] Example 2. Preparation and verification of exosomes
[0098] Exosomes expressing EGFP-Nanoluc fused with scaffold NGFR, BASP-1, PTGFRN, CD63 and MFGE8, as well as native Expi 293F exosomes (named NGFR-293Evs, BASP-1-293Evs, PTGFRN-293Evs, CD63-293Evs, MFGE8-293Evs and 293Evs) were prepared respectively.
[0099] 2.1 Passaging 293s cells
[0100] Expi 293F cell recovery density 3-10×10 5 cells / ml, and the cell density was controlled at 0.5-5×10 6 cells / ml.
[0101] 2.2 Cell transfection
[0102] Before transfection, adjust the cell number in step 2.1 to 1-3×10 6 Cells were grown at a concentration of 1-1.5 μg / ml, and the polyethylenimine (PEI) to plasmid ratio was controlled at a range of (1:1) to (4:1). The four plasmids obtained in step (1.2) were transfected into 293s cells according to the above conditions to overexpress NGFR, BASP-1, PTGFRN, CD63, and MFGE8. The cells were cultured at 37°C, 5% CO₂, for 48-72 hours, and the cell culture supernatant was collected for downstream purification.
[0103] 2.3 Exosome purification
[0104] Use the cell culture supernatant collected in step 2.2 to obtain exosome samples for nanoflow cytometry analysis through ultrafiltration, density gradient centrifugation, and molecular sieve filtration.
[0105] 2.4 Exosome Quality Inspection
[0106] The purified exosomes were characterized, and the morphological (TEM) characterization results are shown in Figure 1. The purified product obtained had a typical exosome disc-shaped sinus membrane layer structure.
[0107] In addition, Western blotting was used to detect the expression of exosome markers CD81 and TSG101, as well as the Golgi apparatus marker GM130 and the endoplasmic reticulum marker Calexin, derived from each cell group. The results are shown in Figure 2. Purity (HPLC) characterization results are shown in Figures 3 and 4. As can be seen from Figures 2 to 4, the exosomes obtained from each cell group highly expressed CD81 and TSG101, while no expression of GM130 and Calexin was detected, further indicating that the obtained exosomes were of high purity.
[0108] Example 3. Distribution and abundance characterization of exosomes engineered with novel scaffold proteins
[0109] 3.1 Comparative characterization of exosome scaffold distribution
[0110] Nano-flow was used to detect the proportion of FITC-positive particles in 20 μL of exosomes containing different scaffold proteins and a negative control group, as shown in Figure 5. Figure 5 shows that the NGFR-positive exosome subpopulation accounts for more than 50% of the entire exosome distribution, which is higher than the currently published universal exosome scaffold CD63.
[0111] 3.2 Comparative characterization of exosome scaffold abundance
[0112] use The luciferase reagent was used to detect the Nanoluc enzyme activity in exosomes with the same number of particles of different scaffold proteins and the negative control group, thereby characterizing the abundance of the fusion expression scaffold in the exosomes with the same number of particles, as shown in Figure 6. Figure 6 shows that the abundance of the NGFR scaffold is greater than that of the CD63 scaffold.
[0113] Example 4: A novel scaffold protein truncated protein for achieving exosome localization and loading of foreign substances
[0114] To determine the shortest sequence of NGFR for exogenous substance loading, this example divided the NGFR protein structure based on the internal and external domains of the transmembrane segment, gradually reduced the domains outside and inside the membrane, and finally determined its amino acids 200-338 and named it truncated-NGFR (SEQ ID NO: 6), which is the shortest sequence for exosome-targeted loading.
[0115] The following is the verification of its distribution and abundance in exosomes.
[0116] 4.1 Expression vector construction and preparation
[0117] (1.1) Vector construction
[0118] The C-terminus of truncated-NGFR was fused with EGFP-Nanoluc to construct and verify the expression vector pcDNA3.1-truncated-NGFR-EGFP-Nanoluc.
[0119] (1.2) Plasmid preparation
[0120] Plasmid preparation was the same as that previously commissioned.
[0121] (1.3) Exosome preparation
[0122] The plasmid prepared in (1.2) was transfected into Expi 293 cells, and the preparation, purification and quality control procedures were the same as in Example 2. It was named truncated-NGFR-293Evs.
[0123] 4.2Verification of truncated-NGFR-293Evs loading EGFP into exosomes
[0124] The high-purity exosomes prepared in (1.3) were characterized. Figure 7 shows that the exosomes were nearly 100% pure, with a disc-shaped morphology and a particle size distribution within the normal range for exosomes. The exosome EGFP positivity rate was approximately 19%, demonstrating that truncated-NGFR can load EGFP into exosomes, preserving their localization and loading functions.
[0125] Example 5: NGFR as a scaffold protein fused to RNA binding protein for mRNA loading
[0126] In this example, the RNA-binding proteins selected are the RNA-binding protein MCP protein of MS2 bacteriophage (SEQ ID NO: 7) and L7Ae of archaea (SEQ ID NO: 8), whose recognition sequences are MS2 (SEQ ID NO: 9) and C / D box sequence (SEQ ID NO: 10), respectively. The selected mRNA is the mRNA encoding the fusion protein of protein coagulation factor 9 and Fc.
[0127] 5.1 Expression vector construction and preparation
[0128] (1.1) Vector construction
[0129] 1) The RNA-binding proteins MCP and L7Ae were fused to the C-terminus of NGFR, respectively, and scaffold expression plasmids pcDNA3.1(+)-scaffold protein-MCP / L7Ae (RNA-binding protein) were constructed. NGFR and RNA-binding protein were fused and expressed, making NGFR a scaffold capable of loading mRNA. pcDNA3.1(+)-scaffold protein served as a control.
[0130] 2) Position the RNA binding protein recognition sequence (MCP recognizes MS2, L7Ae recognizes C / D box) at the 3' end of the loaded mRNA, after the stop codon and before the polyA, to construct the mRNA transcription plasmid pcDNA3.1-FIX-Fc-MS2 / C / Dbox (binding protein recognition sequence). pcDNA3.1-FIX-Fc is the corresponding plasmid for the control. (1.2) Plasmid Preparation
[0131] Plasmid preparation was the same as that previously commissioned.
[0132] 5.2 Exosome Preparation
[0133] The scaffold expression plasmid (pcDNA3.1(+)-scaffold protein-MCP / L7Ae) constructed and prepared in 5.1 was co-transfected with the mRNA transcription plasmid (pcDNA3.1-FIX-Fc-MS2 / C / Dbox) to prepare mRNA-loaded exosomes. The preparation steps were the same as in Example 2. Four groups of exosomes were prepared, namely NGFR-MCP-MS2-FICX-Fc 293Evs, NGFR-L7Ae-C / D box-FIX-Fc 293Evs, NGFR-FIX-Fc 293Evs, and NGFR-293Evs. Their morphology, particle size, and purity were analyzed, as shown in Figures 8-11. Figures 8-11 show that the exosome purity was close to 100%, the morphology was a disc-shaped sinus membrane layer structure, and the particle size distribution range was within the normal range for exosomes.
[0134] 5.3 Characterization of exosome-loaded target (FIX 9) mRNA
[0135] Calculation of FIX 9 mRNA in exosome samples:
[0136] 1) Take 200 μl of exosomes to extract total RNA.
[0137] 2) Perform RT-qPCR on RNA to detect the copy number of FIX mRNA in RNA.
[0138] 3) Detect the exosome particle number concentration corresponding to each sample.
[0139] 4) Calculate the average mRNA copy number per exosome.
[0140] As shown in Figure 12, the exosomes NGFR-MCP-MS2-FICX-Fc 293Evs and NGFR-L7Ae-C / D box-FIX-Fc 293Evs that fused and expressed the RNA-binding protein scaffold can increase the mRNA loading amount compared with the NGFR-FIX-Fc 293Evs exosomes. It can be seen that after the fusion of the scaffold protein and the RNA-binding protein, more mRNA can be packaged into the exosomes, realizing the scaffold protein mRNA loading empowerment.
[0141] Example 6: Exosome targeting function
[0142] 6.1 Display of Targeted Antibodies on Exosome Surfaces
[0143] (1.1) Construction of scaffold fusion expression antibody plasmid
[0144] Using NGFR as an antibody display scaffold, an expression vector was constructed to display antibodies on the surface of exosomes distributed within the chimeric scaffold, achieving exosome targeting. The display antibody is human CD19, corresponding to clone FMC63. The plasmid is named pcDNA3.1-CD19scfv-NGFR-EGFP.
[0145] (1.2) Exosome preparation
[0146] Exosomes expressing CD19scfv fusion protein (named CD19scfv-NGFR-EGFP 293Evs), exosomes overexpressing only scaffold protein (named NGFR-EGFP 293Evs), and 293F cell exosomes (named 293Evs) were prepared respectively.
[0147] The 293s cell passaging, cell transfection, and exosome purification processes were the same as in Example 1.
[0148] (1.3) Exosome quality inspection
[0149] The morphology, particle size, and purity of the sample obtained in step (1.2) were analyzed and tested. As shown in Figures 13-15 below, the distribution ratio of CD19scfv-NGFR-EGFP 293Evs in the prepared sample was approximately 60%, the particle size ranged from 40 nm to 200 nm, and the purity was greater than 90%. Electron microscopy observation showed that the exosome morphology was a disc-shaped sinus membrane layer structure.
[0150] (1.4) Functional verification of CD19scfv-NGFR-EGFP 293Evs targeting CD19 antigen
[0151] 1) CD19 antigen was coated on a solid phase carrier Elisa plate at 4°C overnight;
[0152] 2) After washing with PBST buffer, the plate was blocked with 2% BSA at room temperature for 2 h;
[0153] 3) After washing, incubate an equal amount of the exosome sample to be tested at room temperature for 1 hour;
[0154] 4) After washing, incubate with the exosome surface marker CD9 antibody, followed by HRP-labeled secondary antibody;
[0155] 5) After the substrate develops color, the reaction is terminated and the sample absorbance is measured at OD450 to evaluate whether the exosome sample is CD19 antigen-binding exosomes.
[0156] The results in Figure 16 show that CD19scfv on the surface of exosomes can specifically bind to the CD19 antigen, thereby realizing the exosome antigen targeting function.
[0157] 6.2 Targeting Peptide Display on Exosome Surface
[0158] (2.1) Construction of scaffold-fusion expression targeting peptide plasmid
[0159] The exosome-distributed protein NGFR was used as a targeting peptide display scaffold. The displayed targeting peptide was a short peptide derived from the bacteriophage P17 protein that targets hepatocytes, achieving hepatocyte-targeted exosome targeting. The plasmid was named pcDNA3.1-gp17-NGFR-EGFP.
[0160] (2.2) Preparation of exosomes
[0161] Exosomes expressing gp17 targeting peptide fusion (named gp17-NGFR-EGFP-Flag 293Evs), exosomes without targeting peptide (named NGFR-EGFP-Flag 293Evs) and 293 original exosomes (named 293Evs) were prepared respectively.
[0162] The 293s cell passaging, cell transfection, and exosome purification processes were the same as in Example 1.
[0163] (2.3) Quality control of exosomes
[0164] The particle size, distribution ratio, purity, and morphological analysis data of the exosomes obtained in step (2.2) are shown in Figures 17-19. The distribution ratio of gp17-NGFR-8 293Evs in the exosome sample is approximately 30%, the particle size ranges from 40 nm to 200 nm, and the purity is greater than 90%. Electron microscopy observation shows that the exosome morphology is a disc-shaped sinus membrane layer structure.
[0165] (2.4) Verification of gp17-NGFR-EGFP-Flag 293Evs targeting function
[0166] Mature liver organoid cells were incubated with gp17-NGFR-EGFP-Flag 293Evs and NGFR-EGFP-Flag 293Evs, respectively. By detecting the Flag tag fused to the scaffold, the binding of exosomes to the liver organoid surface was imaged. As shown in Figures 20-21 below, exosomes containing the targeted peptide, gp17-NGFR-8-EGFP-Flag 293Evs, tightly adhered to the liver organoid surface, forming a tight adsorption film. In contrast, exosomes without the targeted peptide diffused throughout the organoid cells and did not aggregate on the liver cell surface.
[0167] Example 7: Targeted peptide exosomes improve in vivo uptake of exosomes into targeted organs
[0168] The targeting peptide exosomes gp17-NGFR-EGFP-Flag 293Evs prepared in Example 6 were used as the experimental group, and NGFR-EGFP-Flag 293Evs were used as the control group. The animal model was wild-type Balb / c mice, and the exosomes were injected into the tail vein. Animal Experiment Design
[0169] The tissue distribution of the test product in Balb / c mice after a single intravenous injection of exosome-Nluc was observed, and the groups are shown in Table 1 below.
[0170] Table 1
[0171] The specific steps are as follows:
[0172] 1) Body weight: Weigh the animals before receiving and administering the medicine.
[0173] 2) Tissue sampling:
[0174] One hour after administration, animal tissues including heart, liver, spleen, lung, brain, and serum were collected. Group G1 served as the background control, G2 as the experimental group, and G3 as the control group. The total weight of the collected tissues was weighed, and approximately 20 mg of each tissue was uniformly sampled. The exact weight was recorded and the sample was homogenized with grinding beads. After complete homogenization, the sample was centrifuged and the supernatant was collected for later use.
[0175] 3) Chemiluminescence intensity detection of tissue homogenate:
[0176] 4) Adoption Luciferase Assay System kit is used to detect Nanoluc enzyme activity in the homogenate. For specific procedures, please refer to the kit instructions.
[0177] 5) Calculate the total amount of Nanoluc enzyme activity in each tissue to characterize the total amount of exosomes taken up by each tissue.
[0178] The calculation results are shown in Figure 22 below. Compared with the control group, the targeted peptide exosomes increased the distribution of exosomes in the liver.
[0179] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. Any technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.
Claims
1. Application of nerve growth factor receptor or its fragments as extracellular vesicle scaffold protein.
2. The use according to claim 1, characterized in that: The nerve growth factor receptor has at least the amino acid sequence shown in SEQ ID NO:6 or an amino acid sequence having at least 85% sequence identity with SEQ ID NO:
6.
3. The use according to claim 1, characterized in that: The nerve growth factor receptor has an amino acid sequence as shown in SEQ ID NO:1 or an amino acid sequence having at least 85% sequence identity with SEQ ID NO:
1.
4. The use according to claim 1, characterized in that: The extracellular vesicles include one or more of exosomes, microvesicles, apoptotic bodies, tumor vesicles and nanovesicles; and / or The extracellular vesicles are extracellular vesicles localized in hepatocytes; and / or The nerve growth factor receptor or fragment thereof is localized in the extracellular vesicles.
5. An extracellular vesicle, characterized in that The extracellular vesicles include: A scaffold protein, wherein the scaffold protein is a nerve growth factor receptor or a fragment thereof; and Active domain.
6. The extracellular vesicle according to claim 5, characterized in that The nerve growth factor receptor has at least the amino acid sequence shown in SEQ ID NO:6 or an amino acid sequence having at least 85% sequence identity with SEQ ID NO:
6.
7. The extracellular vesicle according to claim 5, characterized in that The nerve growth factor receptor has an amino acid sequence as shown in SEQ ID NO:1 or an amino acid sequence having at least 85% sequence identity with SEQ ID NO:
1.
8. The extracellular vesicle according to claim 5, characterized in that The active domain comprises a polypeptide, a polynucleotide sequence, a compound or any combination thereof, Preferably, the active domain comprises an antisense oligonucleotide (ASO), siRNA, miRNA, shRNA, nucleic acid or any combination thereof, Preferably, the active domain comprises a peptide, a protein, an antibody or an antigen-binding fragment thereof, or any combination thereof, Preferably, the antigen-binding fragment of the antibody comprises scFv, (scFv)2, Fab, Fab', F(ab')2, F(ab1)2, Fv, dAb and Fd fragments, bifunctional antibodies, antibody-related polypeptides or any fragments thereof; and / or The scaffold protein is bound to the active domain directly or through a linker.
9. The extracellular vesicle according to claim 8, characterized in that The active domain comprises a nucleotide binding protein or a fragment thereof, wherein the scaffold protein forms a fusion protein with the nucleotide binding protein or a fragment thereof, Preferably, the nucleotide binding protein or fragment thereof further binds to the polynucleotide sequence, Preferably, the nucleotide binding protein is selected from Ku protein, Sm7 protein, MS2 coat protein, PP7 coat protein, Com RNA binding protein, aptamer ligand, or any combination, functional variant, fragment or domain thereof.
10. An expression system, comprising: A first expression element encoding a scaffold protein, wherein the scaffold protein is a nerve growth factor receptor or a fragment thereof; and A second expression element encodes an active domain. A host cell comprising the expression system according to claim 10 . 12 . A pharmaceutical composition comprising the extracellular vesicle according to claim 5 and a pharmaceutically acceptable carrier.
13. Use of the extracellular vesicle according to any one of claims 5 to 9 in the preparation of a medicament for preventing or treating a disease.
14. The use according to claim 13, characterized in that The disease includes cancer, inflammatory disease, neurodegenerative disease, central nervous system disease or metabolic disease, and / or The extracellular vesicles are administered intravenously, intraperitoneally, nasally, orally, intramuscularly, subcutaneously, parenterally, or intratumorally.
Citation Information
Patent Citations
Peripheral brain derived neurotrophic factor (proBDNF) for regulating pain as inflammatory medium
CN107303389A
Engineered extracellular vesicles and uses thereof
CN113286603A
Scaffold proteins derived from epidermal growth factor, lectin and Tat proteins
CN113307857A
Compositions of exosomes and aav
CN114008069A
Methods of treating neuroinflammation
WO2021184020A1
